Global Duchenne Muscular Dystrophy Drugs Market Report 2023: Sector is Expected to Reach $4 Billion by 2028 at a CAGR of 11.88% - ResearchAndMarkets.com

Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, May 18, 2023
Information
Tags: 
Health, Pharmaceutical, Urbanization, Male, Loss, Duchenne muscular dystrophy, Therapy, Prevalence, Research, Genetic disorder, Walking, DMD, Patient, Dystrophin, Growth, Diagnosis, R, Muscular dystrophy, Atrophy, Pharmaceutical industry, Medical device
⚠ generated by AI ↴
Organisation: 
RESEARCH AND MARKETS, RESEARCHANDMARKETS.COM
Summary
Key Points: 
  • Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well.
  • The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles.
  • The publisher provides an analysis of the key trends in each segment of the global Duchenne muscular dystrophy drugs market, along with forecasts at the global, regional, and country level from 2023-2028.
  • Our report has categorized the market based on product type, therapeutic approach, and end user.


The "Duchenne Muscular Dystrophy Drugs Market by Product Type, Therapeutic Approach, End User, and Region 2023-2028" report has been added to ResearchAndMarkets.com's offering.

The global Duchenne muscular dystrophy drugs market size reached US$ 2.04 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 4.00 Billion by 2028, exhibiting a CAGR of 11.88% during 2022-2028.

Companies Mentioned

  • FibroGen Inc.
  • Italfarmaco S.p.A.
  • NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
  • PTC Therapeutics Inc.
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics Inc.

The rising prevalence of Duchenne muscular dystrophy among the masses, the increasing number of new product approvals and launches, and favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, represent some of the key factors driving the market.

Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well. The symptoms of this disorder include difficulty walking, standing, and sitting, as well as speech difficulties, which can result in progressive weakness and loss, also known as atrophy, in the skeletal and heart muscles.

The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Dystrophin is a key protein that maintains muscular integrity, and its absence or abnormality causes DMD. As a result, most of the drugs for the treatment of DMD are dystrophin-based.

Some of the other primary treatment strategies for DMD also include genetic therapies linked to specific mutations which restore dystrophin production, membrane stabilization or upregulation of compensatory proteins, and a reduction of the inflammatory cascade and/or enhancement of muscle regeneration.

The rising number of new product approvals and launches by the major manufacturers is a significant factor driving the growth of the market. This can be attributed to the growing incidences of Duchenne muscular dystrophy among the masses. In line with this, a considerable rise in clinical trials, along with the presence of strong pipeline of products, is providing an impetus to the market.

Moreover, the advent of mutation-specific therapies due to continual innovations in diagnostics is also impacting the market positively. Besides this, extensive research and development (R&D) activities focusing on accurate diagnosis and treatment of DMD for under served categories, such as infants, females, and non-ambulant patients, are propelling the market.

However, the shortage of standardized procedures for the examination of the clinical efficacy of drugs, delayed diagnosis and prediction, and the rising costs of genetic therapeutics are acting as growth-restraining factors for the market.

On the contrary, favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, are contributing to the market growth. Some of the other factors creating lucrative growth opportunities in the market include rapid urbanization, improving medical infrastructure, emerging trend of product premiumization, and inflating disposable incomes of the masses.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the global Duchenne muscular dystrophy drugs market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on product type, therapeutic approach, and end user.

Product Type Insights:

  • Corticosteroids
  • Prednisolone
  • Prednisone
  • Deflazacort
  • Pain Management Drugs

The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the product type. This includes corticosteroids (prednisolone, prednisone and deflazacort) and pain management drugs. According to the report, corticosteroids represented the largest segment.

Therapeutic Approach Insights:

  • Mutation Suppression
  • Exon Skipping
  • Steroid Therapy

The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the therapeutic approach. This includes mutation suppression, exon skipping, and steroid therapy. According to the report, exon skipping represented the largest segment.

End User Insights:

  • Hospitals
  • Clinics
  • Home Care Settings

A detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the end user has also been provided in the report. This includes hospitals, clinics, and home care settings. According to the report, hospitals accounted for the largest market share.

Key Questions Answered in This Report:

  • How has the global Duchenne muscular dystrophy drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global Duchenne muscular dystrophy drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive Duchenne muscular dystrophy drugs markets?
  • What is the breakup of the market based on the product type?
  • What is the breakup of the market based on the therapeutic approach?
  • What is the breakup of the market based on end user?
  • What is the competitive structure of the global Duchenne muscular dystrophy drugs market?
  • Who are the key players/companies in the global Duchenne muscular dystrophy drugs market?

For more information about this report visit https://www.researchandmarkets.com/r/xdji5d

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Copyright: 
Copyright Business Wire 2023